NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Hold” from Brokerages

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned an average rating of “Hold” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $11.5714.

A number of research analysts have recently commented on the company. Leerink Partners set a $14.00 price target on NeoGenomics in a report on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Needham & Company LLC raised their target price on shares of NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Benchmark restated a “hold” rating on shares of NeoGenomics in a research report on Wednesday. Finally, Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th.

Insiders Place Their Bets

In other news, EVP Alicia C. Olivo sold 20,916 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total value of $250,992.00. Following the sale, the executive vice president owned 31,083 shares of the company’s stock, valued at approximately $372,996. The trade was a 40.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the transaction, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at $1,520,387.50. This represents a 15.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On NeoGenomics

Several hedge funds have recently made changes to their positions in NEO. First Light Asset Management LLC lifted its stake in NeoGenomics by 45.0% during the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after purchasing an additional 3,080,837 shares during the last quarter. Greenhouse Funds LLLP increased its holdings in shares of NeoGenomics by 57.8% in the second quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock valued at $54,322,000 after buying an additional 2,722,823 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of NeoGenomics during the 4th quarter valued at $19,182,000. American Capital Management Inc. boosted its stake in shares of NeoGenomics by 120.9% during the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock worth $18,105,000 after acquiring an additional 1,283,390 shares in the last quarter. Finally, Aberdeen Group plc grew its holdings in shares of NeoGenomics by 127.1% in the 4th quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock worth $21,156,000 after acquiring an additional 1,006,676 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Price Performance

NASDAQ NEO opened at $9.89 on Monday. The company has a 50-day moving average price of $12.06 and a two-hundred day moving average price of $10.21. NeoGenomics has a 52 week low of $4.72 and a 52 week high of $13.74. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -11.77 and a beta of 1.58. The company has a current ratio of 4.26, a quick ratio of 3.94 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative return on equity of 3.10% and a negative net margin of 14.85%.The business had revenue of $190.17 million during the quarter, compared to the consensus estimate of $188.25 million. During the same period in the previous year, the firm posted $0.04 earnings per share. The business’s revenue was up 10.6% on a year-over-year basis. Analysts forecast that NeoGenomics will post -0.2 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.